What Do We Know About Covid 19 Implications For Cardiovascular Disease

COVID-19 Consequences on Cardiovascular System: Immediate, Intermediate, and Long-Term Complications covers all the aspects related with the interplay between SARS-COV-2 infection and the cardiovascular system, from bench to bedside and from acute infection to long-term complications. Written by a team of experts, this book is a one-stop-shop reference for both healthcare professionals and researchers who require a comprehensive view into the deleterious effects of COVID-19 on the cardiovascular system, the relationship of cardiovascular risk factors with COVID-19 prognosis, and further insights on the biomarkers that currently make it possible to predict and monitor the evolution of the disease at the cardiovascular level. Scientific evidence demonstrates that while COVID-19 primarily affects the lungs, it also affects multiple organs, particularly the cardiovascular system, with its most common complications being arrhythmia, cardiac injury, fulminant myocarditis, heart failure and pulmonary embolism. Covers all the current scientific pieces of evidence about the effects of COVID-19 on the heart and cardiovascular system from both a basic and a clinical point of view. Discusses immediate, intermediate, and long-term complications of COVID-19 on the cardiovascular system. Includes studies conducted worldwide by well-known experts in related fields.

This book is the first comprehensive approach on COVID-19 cardiac complications, both during the acute phase as well as in the long-COVID period. It provides an up-to-date and highly illustrated summary of the biology of SARS-CoV-2, the course of COVID-19, risk factors that worsen the disease in COVID-19 patients, clinical features of COVID-19 patients, COVID-19 cardiological complications, treatment, and prevention methods, and long-term cardiological aspects of COVID-19. Chapters provide the reader with a contemporary perspective on the emerging links between COVID-19 and cardiovascular disease. In addition, this volume discusses the clinical implications and therapeutic goals in patients with COVID-19 and cardiac complications, as well as possible therapeutic options. It also offers clear recommendations on how to manage (both non- and pharmacologically) to avoid the increased number of COVID-19 related deaths due to CVD and its risk factors. Cardiovascular Complications of COVID-19 will be the primary resource for physicians, residents, fellows, and nursed and medical students in the fields of cardiology and COVID-19/infectious diseases as well as healthcare providers that initiate preventive activities and dedicated programs.

Scientific evidence demonstrates that while COVID-19 primarily affects the lungs, it also affects multiple organs, particularly the cardiovascular system; its most common complications are arrhythmia, cardiac injury, fulminant myocarditis, heart failure, and pulmonary embolism. COVID-19’s Consequences on the Cardiovascular System: Immediate, Intermediate, and Long-Term Complications covers all aspects related to the interplay between SARS-COV-2 infection and the cardiovascular system, from bench to bedside and from acute infection to long-term complications. Written by a team of experts, this book is a one-stop-shop reference for healthcare professionals and researchers who require a comprehensive view of the deleterious effects of COVID-19 on the cardiovascular system. It discusses the relationship of cardiovascular risk factors with COVID-19 prognosis. It offers further insights into the biomarkers that currently make it possible to predict and monitor the evolution of the disease at the cardiovascular level.

This important reference, edited by Ronald Ross Watson and Betsy Dokken, collects the research needed to make the distinct connection between pre-diabetes, diabetes, and cardiovascular disease. Glucose Intake and Utilization in Pre-Diabetes and Diabetes: Implications for Cardiovascular Disease explains the mechanisms of progression from pre-diabetes to diabetes to cardiovascular disease. Since pre-diabetes and diabetes are important cardiovascular disease risk factors, and impaired glucose metabolism among cardiac patients is extremely prevalent, the importance of reviewing pre-diabetes and its involvement in CVD complications is vital as one applies food and glycemic control to slow progress to diabetes and heart disease. The book further focuses on glucose intake and utilization in diabetes, including coverage of diabetes in the development and pathology of cardiovascular disease, risks and epidemiology of cardiovascular problems promoted by diabetes, macrovascular effects and their safety in therapy of diabetics, beta cell biology and therapy of diabetes, and nutrition to modulate diabetes.

This book is a concise, portable handbook that focuses on the clinical use of mechanical blood pumps. All aspects of mechanical circulatory support are addressed, including patient selection, preoperative preparation, operative management, anesthetic considerations and conduct of cardiopulmonary bypass, postop management including complications associated with blood pump use and long-term care and rehabilitation.

In 1996, the Institute of Medicine (IOM) released its report Telemedicine: A Guide to Assessing Telecommunications for Health Care. In that report, the IOM Committee on Evaluating Clinical Applications of Telemedicine found telemedicine is similar in most respects to other technologies for which better evidence of effectiveness is also being demanded. Telemedicine, however, has some special characteristics-shared with information technologies generally-that warrant particular notice from evaluators and decision makers. Since that time, attention to telehealth has continued to grow in both the public and private sectors. Peer-reviewed journals and professional societies are devoted to telehealth, the federal government provides grant funding to promote the use of telehealth, and the private technology industry continues to develop new applications for telehealth. However, barriers remain to the use of telehealth modalities, including issues related to reimbursement, licensure, workforce, and costs. Also, some areas of telehealth have developed a stronger evidence base than others. The Health Resources and Service Administration (HRSA) sponsored the IOM in holding a workshop in Washington, DC, on August 8-9 2012, to examine how the use of telehealth technology can fit into the U.S. health care system. HRSA asked the IOM to focus on the potential for telehealth to serve geographically isolated individuals and extend the reach of scarce resources while also emphasizing the quality and value in the delivery of health care services. This workshop summary discusses the evolution of telehealth since 1996, including the increasing role of the private sector, policies that have promoted or delayed the use of telehealth, and consumer acceptance of telehealth. The Role of Telehealth in an Evolving Health Care Environment: Workshop Summary discusses the current evidence base for telehealth, including available data and gaps in data; discuss how technological developments, including mobile telehealth, electronic intensive care units, remote monitoring, social networking, and wearable devices, in conjunction with the push for electronic health records, is changing the delivery of health care in rural and urban environments. This report also summarizes actions that the U.S. Department of Health and Human Services (HHS) can undertake to further the use of telehealth to improve health care outcomes while controlling costs in the current health care environment.

In December 2019, the world witnessed the occurrence of a new coronavirus to humanity. The disease spread quickly and became known as a pandemic globally, affecting both society and the health care system, both the elderly and young groups of people, and both the men’s and women’s groups. It was a universal challenge that immediately caused a surge in scientific research. Be a part of a world rising in fighting against the pandemic, the Coronavirus Disease - COVID-19 was depicted in the early days of the pandemic, but updated by more than 200 scientists and clinicians to include many facets of this new infectious pandemic, including i, characteristics, ecology, and evolution of coronaviruses; ii, epidemiology, genetics, and pathogenesis (immune responses and oxidative stress) of the disease; iii, diagnosis, prognosis, and clinical manifestations of the disease in pediatrics, geriatrics, pregnant women, and neonates; iv, challenges of co-occurring the disease with tropical infections, cardiovascular diseases, hypertension, and cancer and to the settings of dentistry, hematology, ophthalmology, and pharmacy; v, transmission, prevention, and potential treatments, ranging from supportive ventilator support and nutrition therapy to potential virus- and host-based therapies, immune-based therapies, photobiomodulation, antiviral photodynamic therapy, and vaccines; vi, the resulting consequences on social lives, mental health, education, tourism industry and economy; and vii, multimodal approaches to solve the problem by bioinformatic methods, innovation and ingenuity, globalization, social and scientific networking, interdisciplinary approaches, and art integration. We are approaching December 2020 and the still presence of COVID-19, asking us to call it COVID (without 19).